TY - JOUR
T1 - Biological markers in breast carcinoma. I. Incidence of abnormalities of CEA, HCG, three polyamines, and three minor nucleosides
AU - Tormey, Douglass C.
AU - Waalkes, T. Phillip
AU - Ahmann, David
AU - Gehrke, Charles W.
AU - Zumwatt, Robert W.
AU - Snyder, Jack
AU - Hansen, Hans
PY - 1975/4
Y1 - 1975/4
N2 - Patients with breast carcinoma were screened for abnormal concentrations of CEA, HCG, putrescine, spermidine, spermine, pseudouridine, N2, N2‐dimethylguanosine, and 1‐methylinosine. Abnormal polyamine levels occurred in less than 15% of the patients. Among the nucleosides, N2, N2‐dimethylguanosine was the most frequently abnormal, occurring in 57% of the patients with metastatic disease. CEA levels were abnormal in 30% of postoperative N+ patients and 74% of patients with metastatic disease, while HCG elevations were found in 45% and 50%, respectively. All the patients with one or more marker abnormalities could be detected by measuring only CEA, N2, N2‐dimethylguanosine, and HCG. Among these three tests, a singular marker abnormality occurred in 35.8% of the patients, and all three tests were abnormal in 21.8% of the patients. The performance of these three tests in each patient revealed one or more abnormalities in 97% of the patients with metastatic disease, and 67% of the postoperative N+ patients.
AB - Patients with breast carcinoma were screened for abnormal concentrations of CEA, HCG, putrescine, spermidine, spermine, pseudouridine, N2, N2‐dimethylguanosine, and 1‐methylinosine. Abnormal polyamine levels occurred in less than 15% of the patients. Among the nucleosides, N2, N2‐dimethylguanosine was the most frequently abnormal, occurring in 57% of the patients with metastatic disease. CEA levels were abnormal in 30% of postoperative N+ patients and 74% of patients with metastatic disease, while HCG elevations were found in 45% and 50%, respectively. All the patients with one or more marker abnormalities could be detected by measuring only CEA, N2, N2‐dimethylguanosine, and HCG. Among these three tests, a singular marker abnormality occurred in 35.8% of the patients, and all three tests were abnormal in 21.8% of the patients. The performance of these three tests in each patient revealed one or more abnormalities in 97% of the patients with metastatic disease, and 67% of the postoperative N+ patients.
UR - http://www.scopus.com/inward/record.url?scp=0016761047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016761047&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(197504)35:4<1095::AID-CNCR2820350412>3.0.CO;2-7
DO - 10.1002/1097-0142(197504)35:4<1095::AID-CNCR2820350412>3.0.CO;2-7
M3 - Article
C2 - 1116102
AN - SCOPUS:0016761047
SN - 0008-543X
VL - 35
SP - 1095
EP - 1100
JO - Cancer
JF - Cancer
IS - 4
ER -